Opportunity for Improved Menopausal Hormone Therapy Prescribing

This Perspective discusses the implications of the recent US Food and Drug Administration (FDA) label change on menopausal hormone therapy for clinicians to better integrate hormone therapy options and personalized, shared decision-making to improve care for midlife women.

Corresponding Author: Deborah Bartz, MD, MPH, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115 (dbartz@bwh.harvard.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.